報價延遲最少15分鐘:2025/06/02 07:31 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.34 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
40.06/-2.03
|
|
企業價值
3.00M
|
| 資產負債 |
|
每股賬面淨值
0.56
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/02 07:31 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders. |